0001171843-22-003619.txt : 20220512 0001171843-22-003619.hdr.sgml : 20220512 20220512100134 ACCESSION NUMBER: 0001171843-22-003619 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 22916178 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_051222.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2022-05-12 2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 12, 2022

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

In this report, "GBT," "Company," "we," "our," and "us" means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.

Item 8.01. Other Events.

On May 12, 2022, Global Blood Therapeutics, Inc. issued a press release titled "GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
   
99.1 Press Release dated May 12, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: May 12, 2022By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an oral presentation of additional data from the Phase 1 study of GBT021601 (GBT601), the company’s next generation sickle hemoglobin (HbS) polymerization inhibitor. In addition, initial findings from the Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey, a global burden of disease study assessing healthcare professional (HCP), patient and caregiver perspectives on the unmet needs in SCD, will be presented at the Congress, which will be held from June 9-12 in Vienna, Austria and online.

“Our data presentations at EHA2022 support the sustained use of Oxbryta for the treatment of hemolytic anemia in sickle cell disease, and the promise of our pipeline to improve clinical outcomes for people living with this devastating condition. Real-world evidence continues to provide valuable insights into what happens every day in clinical practice and supports important decisions regarding care,” said Kim Smith-Whitley, M.D., executive vice president and head of research and development at GBT. “Data presented at this year’s Congress will contribute to the growing body of evidence that could transform the treatment of sickle cell disease.”

Following are highlights of GBT’s presentations at the Congress.

Data from a large retrospective study of 216 patients in the United States treated with Oxbryta in a real-world setting further supports its utility in treating patients with SCD:

  • New data from the multicenter Retrospective Study to Evaluate Outcomes in Patients with Sickle Cell Disease Treated with Oxbryta (RETRO) provide further support that treatment with Oxbryta is associated with increased hemoglobin (Hb) levels and decreased hemolytic markers. These data are consistent with those from the Phase 3 HOPE Study that led to the approval of Oxbryta.

Data from the Phase 1 studies of GBT601, which has shown promise in the clinic, supports its further development:

  • Multiple daily doses of GBT601 were well tolerated in both healthy volunteers and adult SCD patients. In SCD patients, the 100 mg maintenance dose studied resulted in a mean Hb occupancy of more than 30%, increased Hb levels, reduced markers of hemolysis, and improved red blood cell (RBC) health (including improved deformability and less sickling). Additional data will be included with the oral presentation.

Data presented from two abstracts add greater insight into the disease burden and effect of Hb levels on people with SCD:

  • The multinational Sickle Cell Health Awareness, Perspectives and Experiences Survey (SHAPE) assessed HCP perspectives on treating SCD and the patient burden of the disease. Results of the SHAPE survey underscore the negative impact of SCD on quality of life and highlight health inequities in SCD and the need for improved awareness, education and treatments that fully address end-organ damage in SCD.
  • A retrospective analysis of 12 years of data from the Clinical Practice Research Datalink and the Hospital Episode Statistics databases in the UK was sufficient to observe end-organ damage events in patients with SCD. It showed that an increase in Hb of 1 g/dL was associated with a significant reduction in the risk for stroke, pulmonary hypertension, chronic kidney disease, end-stage renal disease, leg ulcers, and pneumonia, supporting the use of therapeutics that increase Hb levels in patients with SCD to protect against organ damage.

A presentation on GBT’s pivotal Phase 3 studies of inclacumab, the company’s P-selectin inhibitor:

  • Currently in progress and enrolling patients, the two pivotal Phase 3 THRIVE studies are evaluating the safety and efficacy of inclacumab in reducing vaso-occlusive crises (VOCs) and readmissions due to VOCs. An additional THRIVE open-label expansion (OLE) study will examine the long-term safety of inclacumab in individuals with SCD.

All abstracts are now available at www.ehaweb.org. Details of the GBT presentations, which will be available in the poster hall and via the virtual event platform, are as follows:

Oral Presentation: Sickle Cell Disease
Abstract # S268: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Results from Phase 1 Studies of GBT021601, a Next-Generation HbS Polymerization Inhibitor for Treatment of Sickle Cell Disease
Presenter: Clark Brown, M.D., Ph.D., Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory School of Medicine, Atlanta, GA, USA
Sunday, June 12, 2022, 11:30 -12:45 CEST

Poster Session: Sickle Cell Disease
Abstract # P1487: Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) Survey: Findings on the Burden of Sickle Cell Disease on Patients and Their Unmet Needs as Reported by Healthcare Professionals
Presenter: Baba Inusa, M.D., Department of Paediatric Haematology, Guy’s and St Thomas’ Hospital, London, UK
Friday, June 10, 2022, 16:30 - 17:45 CEST

Abstract # P1486: Trials in Progress - The THRIVE Studies Evaluating the Efficacy, Safety, and Long-Term Treatment with Inclacumab, a P-Selectin Inhibitor, in Patients with Sickle Cell Disease
Presenter: Biree Andemariam, M.D., New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT, USA
Friday, June 10, 2022, 16:30 - 17:45 CEST

Abstract # P1485: A Multicenter, Retrospective Study on Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor
Presenter: Biree Andemariam, M.D., New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT, USA
Friday, June 10, 2022, 16:30 - 17:45 CEST

Abstract # P1488: Association Between Hemoglobin Levels and End-Organ Damage in Sickle Cell Disease: A Retrospective Linked Primary and Secondary Care Database Analysis in England
Presenter: Paul Telfer, D.M., F.R.C.P., Queen Mary, University of London, UK
Friday, June 10, 2022, 16:30 - 17:45 CEST

About Sickle Cell Disease
Sickle cell disease (SCD) affects more than 100,000 people in the United States,1 an estimated 52,000 people in Europe,2 and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.3 It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.4 SCD is a lifelong inherited rare blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.4 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.4,5,6 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen delivery throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.5,6,7,8 Complications of SCD begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.9

About Oxbryta® (voxelotor)
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, Oxbryta inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to hemolysis and hemolytic anemia, which are primary pathologies faced by every single person living with SCD. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD.

In November 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Oxbryta tablets for the treatment of SCD in adults and children 12 years of age and older, and in December 2021, the FDA expanded the approved use of Oxbryta for the treatment of SCD in patients 4 years of age and older in the United States.10 As a condition of accelerated approval for patients ages 4 and older in the United States, GBT will continue to study Oxbryta in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of the therapy to decrease stroke risk in children 2 to 14 years of age.

In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for the treatment of patients with SCD. Additionally, Oxbryta received the prestigious 2021 Prix Galien USA award for “Best Biotechnology Product” from The Galien Foundation.

Oxbryta has been granted Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), Oxbryta was designated by the European Commission (EC) as an orphan medicinal product for the treatment of patients with SCD, and Oxbryta was granted Promising Innovative Medicine (PIM) designation in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA). In February 2022, the European Commission (EC) granted Marketing Authorization for Oxbryta for the treatment of hemolytic anemia due to SCD in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). In addition, the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates (UAE) has granted marketing authorization for Oxbryta for the treatment of SCD in adults and children 12 years of age and older.

Please click here for Important Safety Information and full Prescribing Information including Patient Information for Oxbryta in the U.S.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, commitment, dedication, focus, goals, mission, vision, and positioning; the safety, efficacy, and mechanism of action of Oxbryta, and other product characteristics; the commercialization, awareness, delivery, availability, use, and commercial and medical potential of Oxbryta, including the use, significance and potential of related initiatives; presentation of data at EHA and their significance, including with respect to the use of Oxbryta, the potential of GBT’s pipeline, the further development of GBT601, and the use of therapeutics that increase Hb levels; the significance and use of real-world evidence; the impact of this year’s Congress, including in contributing to evidence to transform the treatment of SCD; ongoing and planned studies, clinical trials and registries, and related protocols, activities, timing, and other expectations; impacting the treatment, care, and course of SCD and mitigating related complications; safety, efficacy, mechanism of action, advancement and potential of GBT’s drug candidates and pipeline; and working on new targets and discovering, developing, and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control, including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities, and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing, and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT is continuing to establish its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for research, development, manufacture, distribution, and commercialization activities; government and third-party payer actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive treatments and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review, or approval; compliance with obligations under the Pharmakon loan; and the timing and progress of activities under GBT’s collaboration, license and distribution agreements; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

References

  1. Centers for Disease Control and Prevention website. Sickle Cell Disease Research. https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-understanding-sickle-cell-disease.html. Accessed February 23, 2022.
  2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125 Accessed February 23, 2022.
  3. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed February 23, 2022.
  4. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022.
  5. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
  6. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  7. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760. 
  8. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  9. Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.
  10. Oxbryta (voxelotor) tablets and tablets for oral suspension prescribing information. South San Francisco, Calif. Global Blood Therapeutics, Inc.; December 2021.
  11. Ataga K. et al. N Engl J Med. 2017;376(5):429-439.

Contact Information:
Steven Immergut (media)
+1 650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
+1 650-351-7881
croberts@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2022
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_051222_htm.xml IDEA: XBRL DOCUMENT 0001629137 2022-05-12 2022-05-12 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2022-05-12 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_051222.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_051222.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_051222.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_051222.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_051222.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-003619-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-003619-xbrl.zip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end